Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Mar 20;33(171):230151.
doi: 10.1183/16000617.0151-2023. Print 2024 Jan 31.

Inhaled versus systemic corticosteroids for acute exacerbations of COPD: a systematic review and meta-analysis

Efthymia Papadopoulou  1   2 , Sulaiman Bin Safar  3   2 , Ali Khalil  3 , Jan Hansel  3   4 , Ran Wang  3   5 , Alexandru Corlateanu  6 , Konstantinos Kostikas  7 , Stavros Tryfon  1 , Jørgen Vestbo  8   5 , Alexander G Mathioudakis  3   5
Affiliations
Meta-Analysis

Inhaled versus systemic corticosteroids for acute exacerbations of COPD: a systematic review and meta-analysis

Efthymia Papadopoulou et al. Eur Respir Rev. .

Abstract

This meta-analysis compares the efficacy and safety of inhaled versus systemic corticosteroids for COPD exacerbations.Following a pre-registered protocol, we appraised eligible randomised controlled trials (RCTs) according to Cochrane methodology, performed random-effects meta-analyses for all outcomes prioritised in the European Respiratory Society COPD core outcome set and rated the certainty of evidence as per Grading of Recommendations Assessment, Development and Evaluation methodology.We included 20 RCTs totalling 2140 participants with moderate or severe exacerbations. All trials were at high risk of methodological bias. Low-certainty evidence did not reveal significant differences between inhaled and systemic corticosteroids for treatment failure rate (relative risk 1.75, 95% CI 0.76-4.02, n=569 participants); breathlessness (mean change: standardised mean difference (SMD) -0.11, 95% CI -0.36-0.15, n=239; post-treatment scores: SMD -0.18, 95% CI -0.41-0.05, n=293); serious adverse events (relative risk 1.47, 95% CI 0.56-3.88, n=246); or any other efficacy outcomes. Moderate-certainty evidence implied a tendency for fewer adverse events with inhaled compared to systemic corticosteroids (relative risk 0.80, 95% CI 0.64-1.0, n=480). Hyperglycaemia and oral fungal infections were observed more frequently with systemic and inhaled corticosteroids, respectively.Limited available evidence suggests potential noninferiority of inhaled to systemic corticosteroids in COPD exacerbations. Appropriately designed and powered RCTs are warranted to confirm these findings.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare no conflict of interest related to this work. E. Papadopoulou, S. Bin Safar, A. Khalil, J. Hansel, R. Wang and A. Corlateanu report no conflicts of interest. K. Kostikas reports grants or contracts from AstraZeneca, Boehringer Ingelheim, Chiesi, Innovis, ELPEN, GSK, Menarini, Novartis and NuovoAir, consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, ELPEN, GSK, Menarini, Novartis, Pfizer and Sanofi Genzyme, honoraria from Alector Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Chiesi, ELPEN, GILEAD, GSK, Menarini, MSD, Novartis, Sanofi Genzime, Pfizer and WebMD, and a leadership role as a member of the GOLD assembly, not related to this work. S. Tryfon reports honoraria from ELPEN, GSK, AstraZeneca, Chiesi and Menarini and participation on advisory boards for ELPEN, GSK, AstraZeneca and Menarini, not related to this work. J. Vestbo reports consulting fees from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Teva, and honoraria from AstraZeneca, Chiesi and GSK, not related to this work. A.G. Mathioudakis reports honoraria from GSK not related to this work.

Figures

FIGURE 1
FIGURE 1
Risk-of-bias table.
FIGURE 2
FIGURE 2
Forest plots featuring the overall effect estimates for the main outcomes. a) Treatment failure during the intervention. b) Breathlessness, mean change (pre-treatment to post-treatment). c) Breathlessness, post-treatment score. d) Serious adverse events during treatment. e) Any adverse event during treatment. f) Health-related quality of life, post-treatment score. CS: corticosteroids; M-H: Mantel–Haenszel method; IV: inverse variance method; SMD: standardised mean difference.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) . Chronic Obstructive Pulmonary Disease (COPD). www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-d... Date last updated: 16 March 2023. Date last accessed: 15 June 2023.
    1. Wedzicha JA, Wilkinson T. Impact of chronic obstructive pulmonary disease exacerbations on patients and payers. Proc Am Thorac Soc 2006; 3: 218–221. doi:10.1513/pats.200510-114SF - DOI - PubMed
    1. Singh D, Kolsum U, Brightling CE, et al. . Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014; 44: 1697–1700. doi:10.1183/09031936.00162414 - DOI - PubMed
    1. Mathioudakis AG, Janssens W, Sivapalan P, et al. . Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax 2020; 75: 520–527. doi:10.1136/thoraxjnl-2019-214484 - DOI - PMC - PubMed
    1. Bafadhel M, McKenna S, Terry S, et al. . Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662–671. doi:10.1164/rccm.201104-0597OC - DOI - PubMed

Substances